Cancer Research & Biostatistics
Seattle, WA Doing business as Crab
- UEI
- PNQDLXQ6RGD5
- CAGE
- 924M4, 3UWG5
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1505 Westlake Ave N #750, Seattle, WA 98109, USA
- Website
- crab.org
- Founded
- 1997
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Consumer Staples
- Food, Beverage & Tobacco
- Food Products
- Agricultural Products
- SIC code
- 09 Fishing, Hunting, & Trapping
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$11,166 |
| FY2025 | $0 |
| FY2024 | -$148,598 |
| FY2023 | $2,970 |
Contract awards
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Addressing the cancer burden in south america and the US hispanic and native american populations through clinical… | National Cancer Institute (NIH) | $9,230 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Fred Hutchinson Cancer Center | U10CA180819 | $5,288,059 | |
| New York University | R01CA249981 | $72,111 | |
| Fred Hutchinson Cancer Center | UG1CA287013 | $616,323 | |
| Fred Hutchinson Cancer Center | UG1CA287013 | $300,000 | |
| Fred Hutchinson Cancer Center | U10CA180819 | $5,036,247 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Cancer Research & Biostatistics, operating as CRAB, is a Seattle-based tax-exempt nonprofit that provides biostatistical consultation, clinical trial data management, and statistical software development to the federal government as a subcontractor on National Cancer Institute (NCI) funded research programs (83% of recent awards are sub-awards). The organization works almost exclusively as a sub-recipient under grants anchored at Fred Hutchinson Cancer Center and New York University, with minimal prime contracting activity—a single $64,950 purchase order from the Department of Veterans Affairs in September 2026 for senior biostatistician services supporting the Precision Oncology Program.
CRAB's federal footprint is heavily concentrated in NCI-funded clinical trial infrastructure. Of eighteen recent awards spanning 2019 to 2026, sixteen are sub-grant awards from the National Cancer Institute; the remaining two are VA purchase orders totaling $324 thousand in combined potential value. The organization does not hold parent contract vehicles or GSA schedules. CRAB's core capability set centers on Statistics and Data Management Center (SDMC) operations for the SWOG cancer clinical trials network, including statistical analysis programming, electronic data capture (EDC) system design in platforms such as Medidata RAVE, database development and security, and clinical trial protocol support. Representative sub-award work includes ongoing SWOG SDMC faculty and staff support for design, conduct, and analysis of scientifically sound clinical trials under a recurring Fred Hutchinson sub-grant (multiple awards dated 2024–2026), NCI Cancer Screening Research Network (CSRN) applications development and data management for study builds in RAVE supporting 10–15 sites (awards dated March 2024, April 2025, and March 2026), 21 CFR Part 11 compliance scoping for potential FDA submission across CSRN data systems (October 2024), and CSRN Vanguard Study enhancements including specimen tracking and multilingual questionnaire capability (November 2025). CRAB has also performed work on NCI Precision Medicine Initiative projects including MyeloMATCH patient screening and NCI middleware integration (December 2023) and supported mutational analysis research on multiple myeloma incidence under a New York University sub-award (December 2024).
Activity has grown modestly over five years—two awards in 2021 and 2023, six in 2024, three in 2025, and four in 2026—with obligated dollars substantially exceeding potential value across the portfolio ($19.4 million obligated against $324 thousand in combined potential ceiling, a ratio indicating significant scope expansion and recurring renewal of standing sub-awards). Customer concentration is extreme: the National Cancer Institute accounts for 16 of 18 awards and dominates the sub-award footprint through Fred Hutchinson as prime, with the VA accounting for the sole prime contracting opportunity. CRAB's role is embedded within NCTN (National Clinical Trials Network) governance and does not compete on open federal procurement vehicles.
Quick answers
Is Cancer Research & Biostatistics registered in SAM.gov?
Yes. Cancer Research & Biostatistics's SAM.gov registration is active through April 22, 2027.
What is Cancer Research & Biostatistics's most recent federal award?
Cancer Research & Biostatistics's most recent federal contract award is Cancer research and biostatistics senior BIO statistician for continuation of survey analysis (36C24526P0550), from Veterans Integrated Service Network 5 (VHA), on September 15, 2026.
On GovTribe
See Cancer Research & Biostatistics's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors